Francisco J. Esteva, Chief of Hematology and Oncology at Lenox Hill Hospital, highlighted the significance of AI-based tools at SABCS25 on LinkedIn. These tools are crucial for predicting outcomes in early breast cancer and identifying early therapy responses. Notably, varied methodologies—traditional pathology and innovative foundation models applied to digital slides—yielded comparable results when integrated with clinical data and utilized as locked assays for both prognostic and treatment response evaluations. Esteva emphasizes a paradigm shift in clinical discussions; the focus now shifts from whether AI can provide valuable predictions to how to properly validate these tools against existing assays. The goal is to use AI effectively in therapy selection while avoiding increased complexity and ensuring patients do not face overtreatment. This evolving dialogue underscores the potential of AI to enhance precision medicine in oncology.
For more insights on advancements in breast cancer treatment, explore additional posts from Francisco J. Esteva.
Source link
